A

federal appeals court on Monday struck another blow against the University of California’s hopes of invalidating key CRISPR patents held by the Broad Institute of MIT and Harvard, ruling unanimously that a U.S. patent board correctly concluded that the Broad’s patents did not “interfere” with those that UC had applied for.

Barring an appeal to the U.S. Supreme Court, which is highly unlikely to accept the case, or a request for the full U.S. Court of Appeals for the Federal Circuit to consider the case, the long and bitter legal saga is largely over, at least in the U.S. (The fight over CRISPR patents in Europe continues.)

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • CRISPR finds certain sequences to change. However, there are only four (4) amino acids involved in DNA and that means there is a limited number of possibilities. If CRISPER is set to cleave at a certain sequence of AA’s, then it will do so every time this sequence exists and it is illogical to presume this sequence ONLY occurs at the sites you are interested in. Therefore, the use of this technique is based upon the random splicing of DNA where ever that sequence exists, meaning there is not only potential benefit but a greater probability for adverse splicing as well. Remember, there is nothing in this technology which focuses the splicing to the area of DNA interest. The adage don’t run with scissors may never be more applicable. This is money driven. Not knowledge or evolutionary driven. The evolutionary process is a process which does not violate viability. CRISPR will bypass the very safeguards that biology has placed. The problems will never be seen because you don’t know what you should be looking for when splicing is occurring at every CGA, or TAT, or whatever sequence you play with resulting in unknown DNA->ribosomal transcription and translation not to mention mitotic effects we aren’t anticipating. If humans have demonstrated anything, it’s the lust for money and power that drives too many.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy